deltatrials
No Longer Available EXPANDED_ACCESS NCT00244686

This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

104317: An Open-Label Compassionate Use Access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome. 201956: A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study. 112562: Expanded Access to Mepolizumab for Patients With Hypereosinophilic Syndrome

Sponsor: GlaxoSmithKline

Conditions Hypereosinophilic Syndrome
Interventions Mepolizumab
Updated 17 times since 2017 Last updated: Apr 24, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hypereosinophilic Syndrome and is currently ongoing. GlaxoSmithKline leads this study, which shows 17 recorded versions since 2026 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Feb 2020 · 16 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – present · 13 months · monthly snapshot

Change History

17 versions recorded

  1. May 2025 — Present [monthly]

    No Longer Available

  2. Sep 2024 — May 2025 [monthly]

    No Longer Available

  3. Jul 2024 — Sep 2024 [monthly]

    No Longer Available

  4. Jan 2021 — Jul 2024 [monthly]

    No Longer Available

  5. Dec 2020 — Jan 2021 [monthly]

    No Longer Available

    Status: Available → No Longer Available

▶ Show 12 earlier versions

  1. Feb 2020 — Dec 2020 [monthly]

    Available

  2. Oct 2018 — Feb 2020 [monthly]

    Available

  3. Jun 2018 — Oct 2018 [monthly]

    Available

  4. May 2018 — Jun 2018 [monthly]

    Available

  5. Apr 2018 — May 2018 [monthly]

    Available

    Phase: NA → None

  6. Oct 2017 — Apr 2018 [monthly]

    Available NA

  7. Aug 2017 — Oct 2017 [monthly]

    Available NA

  8. Jun 2017 — Aug 2017 [monthly]

    Available NA

  9. May 2017 — Jun 2017 [monthly]

    Available NA

  10. Apr 2017 — May 2017 [monthly]

    Available NA

    Status: Recruiting → Available · Phase: PHASE3 → NA

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.